ApoGlyx
2 known investors
ApoGlyx develops first-in-class therapies based on aquaporin inhibitors, targeting inflammatory diseases such as acute pancreatitis. Its drug development work focuses on aquaporin protein channels implicated in inflammation, autoimmunity, cancer, diabetes, and malaria.